Gyre Therapeutics (NASDAQ: GYRE) — Company Overview, News & Financial Data
Gyre Therapeutics innovates drug therapies to address unmet medical needs, focusing on improving patient outcomes through advanced research.
Gyre Therapeutics
Gyre Therapeutics (NASDAQ:GYRE) is dedicated to advancing healthcare through innovation in drug therapies, focusing its efforts on addressing unmet medical needs across a variety of conditions. While the company leans heavily on cutting-edge research and development to fuel its pipeline of novel treatments, it prides itself on a multidisciplinary approach that combines biological insights with advanced technology to develop safer, more effective medications. Gyre Therapeutics’ projects span from early-stage research to late-stage clinical trials, emphasizing collaboration with healthcare professionals and patients to ensure its objectives align with real-world demands. The company aims to significantly improve patient outcomes through its therapeutic advancements, showcasing a commitment to enhancing the quality of life for individuals around the globe.
Snapshot
Operations
Products and/or services of Gyre Therapeutics
- Development of innovative gene therapies targeting chronic and age-related diseases.
- Creation of proprietary platforms for the delivery of genetic material into cells.
- Research into novel methods for managing and treating neurodegenerative disorders.
- Engagement in collaborations with academia and industry to enhance gene therapy techniques.
- Production of scalable and efficient gene editing tools for clinical use.
- Provision of consulting services on genetic therapy strategies and regulatory pathways.
Gyre Therapeutics executive team
- Thomas W. EastlingChief Financial Officer
- Weiguo YeChief Operating Officer
- Ruoyu ChenChief Information Officer
- Ying LuoCEO, President & Director
- Yue XiongChief Scientific Officer & Director
- Joshua BergmannGeneral Counsel & Corporate Secretary
- Seth GoldblumSenior Vice President of Corporate Development
- Jialiang WangExecutive VP & GM
- Jing LiuSenior Vice President of Platform Chemistry
- Mark MarinoSenior Vice President of Clinical Development
Dividend history
Dividends per share paid by Gyre Therapeutics, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2023 | — | — | — | $3.6000 |
| FY2022 | — | — | — | $21.4500 |
| FY2015 | — | — | — | $896.1750 |
Key financials
Reported results for Gyre Therapeutics, in USD.
- Market cap
- 501.5M
- Revenue (TTM)
- 109.8M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.3
- Dividend yield
- —
- Profit margin
- -19.3%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 116.6M | 11.5M | 5M | |
| 105.8M | 16.2M | 12.1M | |
| 113.5M | -67.2M | -92.9M | |
| 102.3M | 9.2M | 2.3M |